Clinical Trial

Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) Study

Study acronym: CIRV2
Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
CIRV2 is a Phase IV randomized, open-label, trial of FDA-approved COVID-19 and/or influenza vaccines (no more than minimal risk) with longitudinal follow-up. In 2025 CIRV2 will compare immunogenicity and reactogenicity of the recombinant Novavax COVID-19 vaccine and the mRNA Pfizer-BioNTech COVID-19 vaccine.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-12-11.
Status change: Recruiting → Active, Not Recruiting 2026-04-30
Trial Details
NCT Number NCT07287137
Lead Sponsor Henry M. Jackson Foundation for the Advancement of Military Medicine
Collaborators: Centers for Disease Control and Prevention, Food and Drug Administration (FDA)
Conditions COVID -19, COVID - 19, COVID 19, Influenza, Respiratory Virus, Respiratory Viruses, Respiratory Virus Infection, Respiratory Virus Infections
Enrollment 54 participants
Start Date 2025-11-12
Primary Completion 2027-09 (estimated)
Study Completion 2027-09 (estimated)
Updated on ClinicalTrials.gov 2026-05-04